Technology ID
TAB-4562
Human TL 1A-transgenic Mouse as a Disease and Therapeutic Model
E-Numbers
E-446-2013-0
Lead Inventor
Siegel, Richard
Co-Inventors
Meylan, Francoise (NIAMS)
Applications
Research Materials
Development Stages
Pre-clinical (in vivo)
Research Products
Animal Models
Lead IC
NIAMS
ICs
NIAMS
This technology includes mouse models of TL 1A diseases, such as inflammatory bowel disease and rheumatoid arthritis, to be used as a platform for studying therapeutic agents. The TNF family cytokine TL 1A co-stimulates T-cells through Its receptor and is required for autoimmune pathology driven by diverse T-cell subsets. Blocking TL 1A in mouse models of these diseases is efficacious blocking TL 1A may be useful for therapy of diseases in which TL 1A plays a pathogenic role.
Commercial Applications
These mice provide a platform for studying the efficacy of therapeutic agents that block human TL 1A-DR3 interactions such as monoclonal anti-TL 1A antibodies and its engineered derivatives.
Competitive Advantages
This 'humanized' rodent model for chronic TL 1A expression is advantageous for testing of therapeutic agents for eventual human use because it allows cost-effective and rapid testing of agents that block the action of this cytokine in an animal model where all pathology is validated to stem from expression of the transgenic cytokine.
Licensing Contact: